Bayer HealthCare Commits $2.5 Million in Funding to Advance Global Hemophilia Research and Patient Care
6/3/2008 2:18:30 PM
Industry-Leading program supports cutting-edge research and clinical projects
Istanbul, Turkey, June 03, 2008 – Bayer HealthCare announced today that it is awarding more than $2.5 million in funding through its Bayer Hemophilia Awards Program (BHAP). 21 individuals from 12 countries will be supported for their hemophilia research activities and clinical projects. The recipients were selected from a 16-member Grant Review and Award Committee, representing clinicians and researchers from around the world and were honored during the World Federation of Hemophilia 2008 World Congress in Istanbul, Turkey.
BHAP is the largest awards program of its kind in hemophilia. It provides funds that support clinical and basic research; encourage new physicians to enter the field; and support continuing education for caregivers. Since 2002, BHAP has provided 138 grants, totaling more than $15 million, to researchers and caregivers around the world. This year’s awards will support a variety of initiatives, from novel approaches for the treatment of hemophilia A and hemophilia B to programs that increase nurse training and improve diagnostic laboratory quality control in developing countries.
“The Hemophilia Awards Program is a strong testament to Bayer’s holistic approach to advancing hemophilia care across the globe,” said Dr. Gunnar Riemann, member of the Executive Committee of Bayer HealthCare. “The program is founded on the belief that we can make much faster progress by leveraging the talent, motivation and passion of individuals from all walks of hemophilia care. I congratulate all of this year’s awardees and wish them the very best in their endeavors.”
A significant issue in the treatment of hemophilia today is the formation of inhibitory antibodies in response to factor VIII replacement therapies; these antibodies bind to the therapeutic factor VIII protein and reduce its ability to effectively stop or prevent bleeding thus increasing the risk for patients. One of this year’s award winners, Dr. Carol Miao, will examine the biological mechanism by which different immunosuppressive regimens induce tolerance. This research could have a tremendous impact on the quality of care for patients, in particular the very young.
“The BHAP program fills a significant gap in hemophilia by funding research and innovative programs aimed at increasing the understanding of the disease and the care of people living with it,” said David Lillicrap, M.D., chairman of the BHAP grant review committee and professor in the department of pathology and molecular medicine, Queen’s University, Canada. “We expect that these high-quality projects will help advance the field of hemophilia, and we look forward to the positive impact their results will have on the global hemophilia community.”
Following are the 2008 award recipients for each of the BHAP categories:
Special Project Awards – provide support for scientific research.
- Anne Angelillo-Scherrer, University Medical Center and University of Lausanne, Switzerland
- Rolf Ljung, Universitetssjukhuset MAS, Malmo, Sweden
- Carol Miao, Seattle Children’s Hospital Research Center, Seattle, Washington, USA
- Kazuo Ohashi, Tokyo Women’s Medical University, Japan
- Guowei Zhang, Blood Research Institute, Milwaukee, Wisconsin, USA
- X. Long Zheng, The Children’s Hospital of Philadelphia, Pennsylvania, USA
Early Career Investigator Awards – provide salary support and research funds for junior faculty members to undertake mentored basic and/or clinical research projects.
